Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 91 of 272 for:    Betamethasone

An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01837576
Recruitment Status : Completed
First Posted : April 23, 2013
Last Update Posted : July 23, 2013
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other safe and effective combination of the two components.

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: Calcipotriol plus BDP gel in different doses Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Study Start Date : April 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Calcipotriol plus BDP gel in different doses
A-E: calcipotriol, BDP gel in different concentrations
Drug: Calcipotriol plus BDP gel in different doses
Topical , Once daily, 3 weeks
Other Name: Daivobet gel




Primary Outcome Measures :
  1. The absolute change in Total Clinical Score (TCS) of clinical symptoms (sum of erythema, scaling and infiltration) [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Absolute change in single clinical symptom score: erythema, scaling, infiltration at end of treatment and individual visits compared to baseline. [ Time Frame: 3 weeks ]
  2. Absolute change in Total Clinical Score (TCS) at individual visits compared to baseline [ Time Frame: 3 weeks ]
  3. The absolute change in total skin thickness and echopoor band thickness at end of treatment compared to baseline. [ Time Frame: 3 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must provide written information.
  • Age 18 years or above.
  • Males, or females subjects.
  • Subjects with lesions of psoriasis vulgaris located on arms and/or legs and/or trunk.
  • Subjects with, in the opinion of the investigator, stable psoriasis
  • Subjects with psoriasis lesions(plaques)assessed by a Total Clinical Score 4 to 9 inclusive but each individual item ≥ 1.
  • Subjects willing and able to follow all the study procedures and complete the whole study.
  • Subjects affiliated to a social security system.
  • Female of childbearing potential with a negative urine pregnancy test

Exclusion Criteria:

  • Female subjects who are pregnant, of childbearing potential and who wish to become pregnant during the study, or who are breast feeding.
  • Systemic treatment with biological therapies within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 halflives (whichever is longer) for experimental biological products prior to randomisation and during the study.
  • Systemic treatments with all other therapies than biologicals, (e.g., corticosteroids, retinoids, immunosuppressants) within the 4 week period prior to randomisation and during the study.
  • Subjects using one of the following topical drugs for the treatment of psoriasis prior to randomisation and during the study: Potent or very potent (WHO group III-IV) corticosteroids (4 weeks).
  • Subjects using of phototherapy prior to randomisation and during the study:
  • PUVA (4 weeks)
  • UVB (2 weeks).
  • Subjects using one of the following topical drugs for the treatment of psoriasis within two weeks prior to randomisation and during the study:
  • WHO group I-II corticosteroids (except if used fortreatment of scalp and/or facial psoriasis),
  • Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. macrolides), Anthracen derivatives, Tar, Salicylic acid
  • Subjects using emollients on the selected plaques within one week before randomisation and during the study.
  • Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g.,beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomization and during the study.
  • Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Subjects with known/suspected disorders of calcium metabolism associated with hypercalcemia within the last 10 years, based on medical history and/or subject interview.
  • History of any severe disease or serious current condition which, in the opinion of the Investigator, would put the subject at risk by participating in the study or would interfere significantly with the evaluation of study results or the study course
  • Subjects who have accepted biopsies with a positive Hepatitis B, Hepatitis C or HIV test
  • Subjects who have received treatment with any non marketed drug substance within the 4 week period prior to randomisation or longer, if the class of the substancerequires a longer washout as defined above
  • Subjects with current participation in any other interventional clinical
  • Subjects with known or suspected hypersensitivity to component(s) of the investigational products.
  • Subjects with any concomitant medical or dermatological disorder(s) which might preclude accurate evaluation of the psoriasis on the test areas.
  • Subjects foreseeing an intensive solar exposure during the study or having been exposed within two weeks preceding the screening visit.
  • Subjects who have accepted the biopsies with any contraindication to skin biopsy procedures.
  • Subjects impossible to contact in case of emergency.
  • In the opinion of the investigator, subjects are unlikely to comply with the Clinical Study Protocol.
  • Subjects who are in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization.
  • Subject under guardianship, hospitalized in a public or private institution, for a reason other than the research or subject deprived of freedom.
  • Subjects previously randomised in this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01837576


Locations
Layout table for location information
France
Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD)
Nice, Nice Cedex 3, France, 06202
Sponsors and Collaborators
LEO Pharma
Investigators
Layout table for investigator information
Principal Investigator: Catherine Queille-Roussel, MD Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD), 06202 Nice Cedex 3, France

Layout table for additonal information
Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT01837576     History of Changes
Other Study ID Numbers: LP0076-1016
First Posted: April 23, 2013    Key Record Dates
Last Update Posted: July 23, 2013
Last Verified: April 2013
Keywords provided by LEO Pharma:
Psoriasis Vulgaris
Calcipotriol
Betamethasone Dipropionate
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Calcitriol
Calcipotriene
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Calcium-Regulating Hormones and Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents